Form 4: Cadrenal CEO Sells Shares Under Pre-Arranged 10b5-1 Plan

Cadrenal Therapeutics CEO and Chairman Quang Pham sold 2,444 shares of common stock in late October 2025 under a pre-arranged trading plan.

Summary

• Quang Pham, CEO and Chairman of Cadrenal Therapeutics, Inc., sold a total of 2,444 shares of common stock.
• The sales occurred on October 24, 2025, and October 27, 2025.
• On October 24, 2025, 1,129 shares were sold at a weighted average price of $14.03 per share, with prices ranging from $13.99 to $14.10.
• On October 27, 2025, 1,315 shares were sold at a weighted average price of $13.99 per share, with prices ranging from $13.99 to $14.00.
• These transactions were executed under a Rule 10b5-1 trading arrangement adopted by Mr. Pham on May 9, 2025.
• Following these sales, Mr. Pham directly beneficially owns 196,089 shares of common stock.
• Additionally, Mr. Pham indirectly beneficially owns 200,000 shares through The PVBQ Living Trust, where he is the Trustee and his child is the sole beneficiary.

Sentiment

Score: 5

Explanation: The sentiment is neutral. While insider selling can be viewed negatively, the execution under a pre-arranged 10b5-1 plan mitigates concerns that the sales are based on new, adverse non-public information. It's likely for personal financial planning.

Positives

• The sales were conducted under a pre-arranged Rule 10b5-1 trading plan, indicating they were not based on new, non-public information.

Negatives

• Insider selling, even under a 10b5-1 plan, can sometimes be perceived negatively by the market as it reduces management's direct equity stake.

Risks

• Potential negative market perception due to insider selling, which could put downward pressure on the stock price.

Industry Context

This Form 4 filing reflects routine insider transaction disclosures common across publicly traded companies, particularly for executives managing personal liquidity or diversification through pre-arranged trading plans.

Related Party Transactions

• Quang Pham indirectly beneficially owns 200,000 shares through The PVBQ Living Trust, where he serves as Trustee and his child is the sole beneficiary. This represents a related party holding.

Stakeholder Impact

• Shareholders may perceive the insider selling as a negative signal, potentially leading to short-term downward pressure on the stock price, despite the sales being pre-planned.

Key Dates

Recommendation

While insider selling can be a negative signal, the execution under a Rule 10b5-1 plan suggests these are pre-scheduled transactions for personal financial management rather than a reaction to new, adverse company developments. Given the lack of other financial or operational updates in this filing, a 'hold' recommendation is appropriate, awaiting further company-specific news or broader market trends for a more definitive stance.

Keywords

Cadrenal Therapeutics, CVKD, Quang Pham, Insider Trading, Form 4, Stock Sale, 10b5-1 Plan, CEO, Chairman